In medical terms, a booster dose is an extra administration of a vaccine after an earlier (prime) dose. After initial immunization, a booster injection or booster dose is a re-exposure to the immunizing antigen. It is intended to increase immunity against that antigen back to protective levels, after memory against that antigen has declined through time. For example, tetanus shot boosters are often recommended every 10 years, after which memory cells specific against tetanus have lost their function or undergone apoptosis.
The need for a booster dose following a primary vaccination is evaluated in several ways. One way is to measure the level of antibodies specific against a disease, a few years after the primary dose is given. Anamnestic response, the rapid production of antibodies after a stimulus of an antigen, is a typical way to measure the need for a booster dose of a certain vaccine. If anamnestic response is high after receiving a primary vaccine many years ago, there is most likely little to no need for a booster dose. People can also measure the active B and T cell activity against that antigen after a certain amount of time that the primary vaccine was administered, or determine the prevalence of the disease in vaccinated populations.
If a patient receives a booster dose but already has a high level of antibody, then a reaction called an Arthus reaction could develop, a localized form of Type III hypersensitivity induced by high levels of IgG antibodies causing inflammation. The inflammation is often self-resolved over the course of a few days, but could be avoided altogether by increasing the length of time between the primary vaccine and the booster dose.
It is not yet fully clear why some vaccines such as hepatitis A and B are effective for life, and some such as tetanus need boosters. The prevailing theory is that if the immune system responds to a primary vaccine rapidly, the body does not have time to sufficiently develop immunological memory against the disease, and memory cells will not persist in high numbers for the lifetime of the human. After a primary response of the immune system against a vaccination, memory T helper cells and B cells persist at a fairly constant level in germinal centers, undergoing cell division at a slow to nonexistent rate. While these cells are long-lived, they do not typically undergo mitosis, and eventually the rate of loss of these cells will be greater than the rate of gain. In these cases, a booster dose is required to "boost" the memory B and T cell count back up again.
Polio booster doses
In the case of the polio vaccine, the memory B and T cells produced in response to the vaccine persist only six months after consumption of the oral polio vaccine (OPV). Booster doses of the OPV were found ineffective, as they, too, resulted in decreased immune response every six months after consumption. However, when the inactive polio vaccine (IPV) was used as a booster dose, it was found to increase the test subjects' antibody count by 39–75%. Often in developing countries, OPV is used over IPV, because IPV is expensive and hard to transport. However, in places where polio is still present, following up an OPV primary dose with an IPV booster may help eradicate the disease.
In the United States, only the IPV is used. In rare cases (about 1 in 2.7 million), the OPV has reverted to a strengthened form of the illness, and caused paralysis in the recipients of the vaccine. For this reason, the US only administers IPV, which is given in four increments (3 within their first year and a half after birth, then one booster dose between the ages 4–6).
Hepatitis B booster doses
The need for a booster dose for hepatitis B has long been debated. Studies in the early 2000s that measured memory cell count of vaccinated individuals showed that fully vaccinated adults (those that received all three rounds of vaccination at the suggested time sequence during infancy) do not require a booster dose later in life. Both the CDC and Canadian National Advisory Committee supported these recommendations by publicly advising against the need for a hepatitis B booster dose. However, immuno-repressed individuals are advised to seek further screening to evaluate their immune response to hepatitis B, and potentially receive a booster dose if their B and T cell count against hepatitis B decrease below a certain level.
Tetanus booster dose
The tetanus disease requires a booster dose every 10 years, or in some circumstances immediately following infection of tetanus. Td is the name of the booster for adults, and differs from the primary dose in that it does not include immunization against pertussis (whooping cough). While the US recommends a booster for tetanus every 10 years, other countries, such as the UK, suggest just two booster shots within the first 20 years of life, but no booster after a third decade. Neonatal tetanus is a concern during pregnancy for some women, and mothers are recommended a booster against tetanus during their pregnancy in order to protect their child against the disease.
Whooping cough booster dose
Whooping cough, also called pertussis, is a contagious disease that affects the respiratory tract. The infection is caused by a bacterium that sticks to the cilia of the lungs, and can be very contagious. Pertussis can be especially dangerous for babies, whose immune system are not yet fully developed, and can develop into pneumonia or result in the baby having trouble breathing. DTaP is the primary vaccine given against pertussis, and children typically receive five doses before the age of seven. Tdap is the booster for pertussis, and is advised in the US to be administered every ten years, and during every pregnancy for mothers. Tdap can also be used as a booster against tetanus.
Upon its invention in the 1950s, the pertussis vaccine was whole-cell (contained the entire inactivated bacterium), and could cause fever and local reactions in people who received the vaccine. In the 1990s, people in the US started using accelular vaccines (contained small portions of the bacterium), that had lower side effects but were also less effective at triggering an immunological memory response, due to the antigen presented to the immune system being less complete. This less effective, but safer vaccine, led to the development of the booster Tdap.
- Tetanus: Prevention, Mayo Clinic, 2006-09-21, archived from the original on 2008-06-24, retrieved 2008-07-17
- Van Damme, Pierre; Van Herck, Koen (2007-03-01). "A review of the long-term protection after hepatitis A and B vaccination". Travel Medicine and Infectious Disease. 1st International Conference of Travel Medicine and Infectious Disease1st International Conference of Travel Medicine and Infectious Disease. 5 (2): 79–84. doi:10.1016/j.tmaid.2006.04.004. PMID 17298912.
- Leuridan, Elke; Damme, Pierre Van (2011-07-01). "Hepatitis B and the Need for a Booster Dose". Clinical Infectious Diseases. 53 (1): 68–75. doi:10.1093/cid/cir270. ISSN 1058-4838. PMID 21653306.
- Committee, Institute of Medicine (US) Vaccine Safety; Stratton, Kathleen R.; Howe, Cynthia J.; Richard B. Johnston, Jr (1994-01-01). "Immunologic Reactions".
- University of the Sciences in Philadelphia; David B. Troy; Joseph Price Remington; Paul Beringer (2005). Remington: the science and practice of pharmacy. Lippincott Williams & Wilkins. ISBN 0-7817-4673-6.
- "Top 20 Questions about Vaccination — History of Vaccines". www.historyofvaccines.org. Retrieved 2016-01-30.
- Charles A Janeway, Jr; Travers, Paul; Walport, Mark; Shlomchik, Mark J. (2001-01-01). "Immunological memory".
- Jafari, Hamid; Deshpande, Jagadish M.; Sutter, Roland W.; Bahl, Sunil; Verma, Harish; Ahmad, Mohammad; Kunwar, Abhishek; Vishwakarma, Rakesh; Agarwal, Ashutosh (2014-08-22). "Efficacy of inactivated poliovirus vaccine in India". Science. 345 (6199): 922–925. doi:10.1126/science.1255006. ISSN 0036-8075. PMID 25146288.
- Roberts, Leslie (2014-08-22). "A one-two punch against polio". Science. 345 (6199): 861–862. doi:10.1126/science.345.6199.861. ISSN 0036-8075. PMID 25146262.
- "Vaccines: VPD-VAC/Polio/main page". www.cdc.gov. Retrieved 2016-02-09.
- "Vaccines: VPD-VAC/Tetanus/main page". www.cdc.gov. Retrieved 2016-02-09.
- Cook, T. M.; Protheroe, R. T.; Handel, J. M. (2001-09-01). "Tetanus: a review of the literature". British Journal of Anaesthesia. 87 (3): 477–487. doi:10.1093/bja/87.3.477. ISSN 0007-0912. PMID 11517134.
- Rodrigo, Chaturaka; Fernando, Deepika; Rajapakse, Senaka (2014-01-01). "Pharmacological management of tetanus: an evidence-based review". Critical Care. 18 (2): 217. doi:10.1186/cc13797. ISSN 1364-8535. PMC . PMID 25029486.
- "Pertussis | Whooping Cough | Complications | CDC". www.cdc.gov. Retrieved 2016-02-16.
- "Vaccines: VPD-VAC/Pertussis/main page". www.cdc.gov. Retrieved 2016-02-16.
- Hartzell, Joshua D.; Blaylock, Jason M. (2014-07-01). "Whooping Cough in 2014 and Beyond: An Update and Review". Chest. 146 (1): 205–214. doi:10.1378/chest.13-2942. PMID 25010963.